Polymorphism in cytochrome P450 2E1 and interaction with other genetic risk factors and susceptibility to alcoholic liver cirrhosis

Khan, Anwar Jamal; Ruwali, Munindra; Choudhuri, Gourdas; Mathur, Neeraj; Husain, Qayyum; Parmar, Devendra

doi:10.1016/j.mrfmmm.2009.02.009

Cited by 32 publications

(19 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies were then filtered to ensure conformity with the inclusion criteria. One study (Lind et al, 2008) was excluded because it investigated families comprised of monozygotic and dizygotic twin pairs; one study (Khan et al, 2009) was excluded because the definition of alcoholism was based on alcohol consumption only; and four studies (Agrawal et al, 2006;Dick et al, 2005Dick et al, , 2006Edenberg et al, 2004) were excluded because the data were not made available after we contacted the authors to request access to the data. In the end, 27 studies (Chang et al, 2002;Covault et al, 2004Covault et al, , 2008Enoch et al, 2009;Fehr et al, 2006;Foley et al, 2004;Han et al, 2008;Hsu et al, 1998;Lappalainen et al, 2005;Li et al, 2002;Lin et al, 2003;Loh et al, 1999Loh et al, , 2000Loh et al, , 2007Lydall et al, 2011;Nishiyama et al, 2005;Onori et al, 2010;Park et al, 2006;Sander et al, 1999;Soyka et al, 2008) met our criteria for inclusion (Supplementary Table 3).…”

Section: Resultsmentioning

confidence: 99%

Association of Gamma-Aminobutyric Acid A Receptor α2 Gene (GABRA2) with Alcohol Use Disorder

Sulovari

Cheng

et al. 2013

Neuropsychopharmacol

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Association of Gamma-Aminobutyric Acid A Receptor α2 Gene (GABRA2) with Alcohol Use Disorder

Sulovari

Cheng

et al. 2013

Neuropsychopharmacol

View full text Add to dashboard Cite

“…It was indicated that the variant of c2 allele makes the CYP2450E1 level increase, which functions by blocking tyrosine phosphorylation of IRS-1 and IRS-2, ultimately resulting in IR and an increased risk of HCC (56). The CYP4502E1*5B (RsaI, -1053C>T) variant is relevant to the improvement of its transcription and enzyme activity, which increase the generation of ROS in alcoholic cirrhotic patients, but not in NAFDL patients (57). Consequently, larger cohort studies should be explored in future research to verify and evaluate the effect of the CYP2E1 Pst I/Rsa I polymorphism-associated NAFLD risk.…”

Section: Cytochrome P4502e1 (Cyp4502e1)mentioning

confidence: 99%

Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease

Wang

Gong

2017

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, the morbidity of which closely correlates with diversity of ethnicity, minority, family and location. Its histology spans from simple steatosis, to nonalcoholic steatohepatitis, which ultimately results in fibrosis, cirrhosis and hepatocellular carcinoma. The accelerating prevalence of NAFLD is due to an incremental incidence of metabolic syndrome that is distinguished by dyslipidemia, glucose impairment, obesity, excessive oxidative stress and adipocytokine impairment. Additionally, the pathogenesis of NAFLD is thought to be a multifactorial and complicated disease associated with lifestyle habits, nutritional factors and genetics. However, the pathogenesis and underlying mechanism in the development of NAFLD caused by genetics remains unclear. People have been increasingly emphasizing on the relationship between NAFLD and gene polymorphisms in recent years, with the aim of having a comprehensive elucidation of associated gene polymorphisms influencing the pathogenesis of the disease. In the current article, the authors attempted to critically summarize the most recently identified gene polymorphisms from the facets of glucose metabolism, fatty acid metabolism, oxidative stress and related cytokines in NAFLD that contribute to promoting the progression of the disease.

show abstract

“…The CYP2E1 frequencies observed in our study are more similar to those found in EuropeanAmericans of European descent (92% *1A/*1A, 7% *1A/*5B and 1% *5B/*5B for RsaI/PstI; 10% *1A and 90% *6 for DraI) (Roy et al 2008). Polymorphisms in CYP2E1 are present at higher frequencies in Asians than any other populations (Garte et al 2001), with a frequency of about 20-30% of the *5B allele (Khan et al 2009). According to the meta-analysis study by Cai (Cai et al 2012) the NAT2 slow genotypes, CYP2E1*1A and GSTM1 null have a modest effect on the genetic susceptibility to hepatotoxicity.…”

Section: Association Among Clinical Factors Genotypes and Atd-inducementioning

confidence: 99%

“…CYP genes are highly polymorphic and the polymorphisms have been associated with altered gene expression and drug adverse reactions (Ingelman Sundberg, 2004, Ingelman Sundberg et al 2007). Polymorphisms in CYP2E1 have been investigated in relation to alcoholism, chronic obstructive pulmonary disease, alcoholic liver cirrhosis, innumerous types of cancer and ATDinduced hepatitis (Kato et al 1992, Arif et al 2007, Boccia et al 2007, Cho et al 2007, Liu et al 2007, Khan et al 2009). …”

Section: Introductionmentioning

confidence: 99%

Polymorphisms in CYP2E1, GSTM1 and GSTT1 and anti-tuberculosis drug-induced hepatotoxicity

Brito

Possuelo

Valim

et al. 2014

An. Acad. Bras. Ciênc.

View full text Add to dashboard Cite

Anti-tuberculosis drug-induced hepatitis (ATD-induced hepatitis) has been linked to polymorphisms in genes encoding drug metabolizing enzymes. N-acetyltransferase 2 (NAT2), cytochrome P450 2E1 (CYP2E1) and glutathione S-transferase (loci GSTM1 and GSTT1) are involved in the metabolism of isoniazid, the most toxic drug for the treatment of tuberculosis (TB). This study was designed to determine the frequency and to evaluate whether polymorphisms at CYP2E1, GSTM1 and GSTT1 genes are associated with drug response, as well as to identify clinical risk factors for ATD-induced hepatitis. A total of 245 Brazilian patients undergoing treatment for TB were genotyped using polymerase chain reaction and restriction fragment length polymorphism and sequencing methods. The frequencies of the CYP2E1 polymorphic alleles RsaI, PstI and DraI are 8%, 8.5% and 12%, respectively. GSTM1 and GSTT1 genes are deleted in 42.9% and 12.4% of the population, respectively. Fifteen patients (6.1%) developed hepatotoxicity. Clinical (HIV, female sex and extrapulmonary TB) and genetic characteristics (CYP2E1 without any mutations, having NAT2 slow acetylator profile) are at higher risk of developing ATD-induced hepatitis in this population. Genotyping for GSTM1 and GSTT1 showed no influence on drug response.

show abstract

Polymorphism in cytochrome P450 2E1 and interaction with other genetic risk factors and susceptibility to alcoholic liver cirrhosis

Cited by 32 publications

References 40 publications

Association of Gamma-Aminobutyric Acid A Receptor α2 Gene (GABRA2) with Alcohol Use Disorder

Association of Gamma-Aminobutyric Acid A Receptor α2 Gene (GABRA2) with Alcohol Use Disorder

Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease

Polymorphisms in CYP2E1, GSTM1 and GSTT1 and anti-tuberculosis drug-induced hepatotoxicity

Contact Info

Product

Resources

About